Across TCGA pan-cancer cohorts, ANKRD19P Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD19P data layer compared with 25 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher ANKRD19P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD19P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
THYM, UCEC, and BRCA are the cancer types where ANKRD19P Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.